Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

(2017) Wenpeng Li et al.   HUMAN GENE THERAPY

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

CAR T-Cell Therapy: Progress and Prospects

(2017) Olivia Wilkins et al.   Human Gene Therapy Methods

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

(2017) Sayed Shahabuddin Hoseini et al.   OncoImmunology

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery

(2016) S C Katz et al.   CANCER GENE THERAPY

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Disialoganglioside GD2 as a therapeutic target for human diseases

(2015) Maya Suzuki et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

(2013) Chan-Juan Shen et al.   Journal of Hematology & Oncology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

How Do Gangliosides Regulate RTKs Signaling?

(2013) Sylvain Julien et al.   Cells

The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

(2012) S Kailayangiri et al.   BRITISH JOURNAL OF CANCER

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

(2012) L. G. Radvanyi et al.   CLINICAL CANCER RESEARCH

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)

(2011) D.-G. Song et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

(2009) E. Yvon et al.   CLINICAL CANCER RESEARCH

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient

(2009) Mepur H. Ravindranath et al.   MELANOMA RESEARCH